Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy?

Urology

Volumn 78, Issue 4, 2011, Pages 868-872

  Mitchell, Christopher R ^a   Umbreit, Eric C ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Karnes, R Jeffrey ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; HEMODILUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; OBESITY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; BODY MASS INDEX; EARLY DETECTION OF CANCER; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053927890     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.060     Document Type: Article

References (14)

1. B.A. Nelson, S.B. Shappell, and S.S. Chang Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer BJU Int 97 2006 1169 1172
2. T.A. Stamey, J.E. McNeal, and C.M. Yemoto Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 1395 1400
3. K.L. Blackwell, D.G. Bostwick, and R.P. Myers Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density J Urol 151 1994 1565 1570
4. T.A. Stamey, N. Yang, and A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
5. R.J. Babaian, P. Troncoso, and L.C. Steelhammer Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability J Urol 154 1995 1808 1812
6. J. Noldus, and T.A. Stamey Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients J Urol 155 1996 232 237
7. T.A. Stamey, M. Caldwell, and J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172 2004 1297 1301
8. A. Ochiai, P. Troncoso, and R.J. Babaian The relationship between serum prostate specific antigen level and tumor volume persists in the current era J Urol 177 2007 903 906
9. C.L. Ogden, M.D. Carroll, and L.R. Curtin Prevalence of overweight and obesity in the United States, 1999-2004 JAMA 295 2006 1549 1555
10. L.L. Baez, R.J. Hamilton, and A.W. Partin Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer JAMA 298 2007 2275 2280
11. L.L. Baez, L. Sun, and B.J. Trock Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy J Urol 182 2009 491 498
12. C.L. Amling, R.H. Riffenburgh, and L. Sun Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy J Clin Oncol 22 2004 439 445
13. S.J. Freedland, W.J. Aronson, and C.J. Kane Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group J Clin Oncol 22 2004 446 453
14. S.A. Siddiqui, B.A. Inman, and S. Sengupta Obesity and survival after radical prostatectomy: a 10-year prospective cohort study Cancer 107 2006 521 529